| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Shuttle Pharmaceuticals Holdings, Inc.$2.92
-0.32 (-9.76%)
Market Cap
3.41 M
EPS
-6.06
P/E Ratio
-
Value Trade
121.83 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
267.24 K
Operating CF
-2.42 M
Total Assets
11.81 M
Total Liabilities
8.46 M
Equity
3.35 M
D/E Ratio
12,345
-12.04 %
Week
-42.35 %
1 Month
-48.47 %
3 Month
-72.14 %
6 Month
-99.99 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
1.09 M
Monthly Burn
806.00 K
Runway
0 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
72.44 K
52 Week Range
0.50 - 6.19
% held by Insiders
6.45 %
% held by Institutions
15.27 %
Enterprise Value
2.53 M
Total Shares
5.85 M
Short %
2.52 %
Float Shares
5.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Shuttle Pharmaceuticals Holdings, Inc.
130Total events
0Upcoming
13Tier-1 (high impact)
2022 – 2026Coverage
Event history 130
Apr 2026
Apr 2026
◆Trial CompletionRopidoxuridineTrial
Phase 2 trial expected to complete over 18-24 months
glioblastomasource ↗
Mar 6, 2026
▼Equity OfferingCorporate
Public offering of common stock and pre-funded warrants for $3.5 million gross proceeds
Mar 2026
◆Trial CompletionRopidoxuridineTrial
Phase 2 trial expected to be completed over 18 to 24 months
glioblastomasource ↗
Feb 2026
2026
◆Enrollment CompleteRopidoxuridineTrial
Target to complete enrollment in the coming year
glioblastomasource ↗
2026
◆Trial CompletionRopidoxuridineTrial
Expected trial completion over 18 to 24 months
glioblastomasource ↗
Oct 10, 2025
Aug 14, 2025
▲Enrollment UpdateRopidoxuridineTrial
63% enrollment achieved in Phase 2 trial of Ropidoxuridine for glioblastoma
glioblastomasource ↗
Jun 24, 2025
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SHPH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SHPH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SHPH▲ +6.3%on this news
United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site
United Dogecoin Inc., recently acquired by Shuttle Pharmaceutical Holdings, aims to become the largest Dogecoin miner by hashrate. The company has purchased ElphaPex DG1+ mining units and secured a renewable energy site. Operations are expected to commence in about 60 days, leveraging low-cost hydroelectric power for efficiency.
Read more →SHPH▲ +6.3%on this newsshared move
United Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting
United Dogecoin has initiated a strategy to enhance its digital infrastructure, focusing on data centers and power generation to support DOGE mining and AI workloads. The company is exploring opportunities in Idaho and Alberta, citing favorable conditions for digital asset mining. This initiative aims to create additional revenue streams and improve operational efficiencies in a competitive market.
Read more →SHPH▼ -6.5%on this news· ran to -19% by day 3
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time
Shuttle Pharmaceuticals Holdings, Inc. has announced a 10-for-1 reverse stock split effective June 11, 2026. This move aims to reduce the number of outstanding shares from approximately 6.37 million to about 637,108 shares. The split is part of the company's strategy to comply with Nasdaq's listing requirements and enhance its long-term capital structure.
Read more →SHPHShuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
Shuttle Pharmaceuticals has finalized its merger with United Dogecoin and confirmed a purchase order for up to 3,000 ElphaPex mining rigs. The rigs will be used for mining Dogecoin and Litecoin, aiming to accumulate these cryptocurrencies as long-term assets. The deployment of the mining fleet is expected to begin within 60 days, enhancing Shuttle's position in the cryptocurrency mining sector.
Read more →SHPH▼ -32.8%on this news
United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation
Shuttle Pharmaceutical Holdings, Inc. has announced a merger with United Dogecoin Inc., aiming to create the largest publicly listed Dogecoin mining company. The merger, supported by an $11 million PIPE financing, will enhance United Dogecoin's mining capacity and operational efficiency. The leadership team, led by CEO Ryan Trasolini, aims to leverage their expertise to establish a strong market position in Dogecoin mining.
Read more →SHPH▼ -32.8%on this newsshared move
Shuttle Merges with United Dogecoin to Become the World’s Largest Public Dogecoin Miner
Shuttle Pharmaceutical Holdings, Inc. has announced a merger with United Dogecoin, aiming to create the largest publicly listed Dogecoin mining company. The merger includes an $11 million PIPE financing and is expected to enhance mining capacity significantly. United Dogecoin's leadership has a strong background in cryptocurrency, positioning the combined entity for growth despite inherent market risks.
Read more →SHPHShuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percenta
Shuttle Pharmaceutical Holdings, Inc. has announced a definitive merger agreement with United Dogecoin Inc. to establish the largest publicly listed Dogecoin mining company. The deal is supported by an $11 million PIPE financing expected to close shortly. The combined entity will leverage United Dogecoin's competitive advantages, including access to new high-efficiency mining rigs and renewable energy sources. Despite the promising outlook, the merger is contingent upon stockholder approval, and the success of its planned mining strategy in the competitive cryptocurrency market will need to be demonstrated.
Read more →SHPH▼ -22.9%on this news· ran to -38% by day 1
RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
Shuttle Pharmaceuticals has launched an upgraded version of its molecule.ai platform, enhancing its capabilities in therapeutic discovery through advanced AI models. This update allows for better evaluation and prioritization of therapeutic candidates, facilitating faster decision-making. The introduction of an autonomous AI agent system aims to streamline complex scientific workflows, potentially reducing costs and timelines in drug development.
Read more →SHPH▲ +5.6%on this news
Shuttle Pharmaceuticals Announces $3.5 Million Public Offering
Shuttle Pharmaceuticals has announced a public offering to raise approximately $3.5 million through the sale of common stock and warrants. The company plans to use part of the proceeds for marketing and general corporate purposes. The offering is expected to close around March 9, 2026, pending customary conditions.
Read more →SHPH▲ +5.6%on this newsshared move
Shuttle Pharmaceuticals Announces $3.5 Million Public Offering GAITHERSBURG, Md.
Shuttle Pharmaceuticals Holdings, Inc. has announced a public offering aimed at raising approximately $3.5 million by issuing 2,238,800 shares of common stock along with warrants to purchase an additional 4,761,200 shares. The company plans to use part of the proceeds for marketing efforts, with the remainder allocated for working capital and corporate purposes. This offering is set to close around March 9, 2026, pending customary closing conditions. The offering has been facilitated by Hutton & Co., the exclusive placement agent.
Read more →SHPH▲ +6.3%on this news· ran to +50% by day 3
Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs – and Why Molecule.ai’s Drug Discovery Platform Matters More Than Ever
Shuttle Pharmaceuticals applauds Utah for becoming the first state to allow AI systems to authorize prescription refills without direct physician involvement. This initiative aims to reduce healthcare costs and improve access, particularly in rural areas. Shuttle's Molecule.ai platform seeks to automate drug discovery processes, minimizing inefficiencies and costs while ensuring safety and oversight. The pilot program may influence future AI regulations in healthcare.
Read more →SHPH▼ -22.3%on this news· ran to -34% by day 3
Shuttle Pharmaceuticals Acquires AI Health Platform
Shuttle Pharmaceuticals has acquired Molecule.ai, a Canadian AI company, for $8 million, with potential additional payments based on performance milestones. This acquisition aims to enhance Shuttle's drug discovery capabilities and advance its mission in precision radiotherapy. Both companies express optimism about the collaboration's potential impact on drug development.
Read more →SHPHShuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00
Shuttle Pharmaceuticals Holdings, Inc. announced a private placement agreement to raise approximately $2.5 million, with shares priced at $4.00 each, above the market rate. The funds will be allocated for marketing and general corporate purposes. The offering is expected to close soon, pending customary conditions.
Read more →SHPH▼ -7.2%on this news
Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform
Shuttle Pharmaceuticals Holdings, Inc. has announced a binding term sheet to acquire the assets of Canadian AI company Molecule for $10 million. This acquisition aims to enhance Shuttle's capabilities in molecular modeling and predictive analytics, crucial for advancing their precision radiotherapy solutions. The deal will involve a mix of cash and stock, contingent on performance milestones.
Read more →SHPHShuttle Executes LOI with Molecule.ai
Shuttle Pharmaceuticals has signed a non-binding letter of intent to acquire Molecule.ai, an AI-driven company focused on drug discovery. The acquisition aims to leverage Molecule.ai's advanced machine learning models to enhance the efficiency and accuracy of therapeutic development. Shuttle will pay $10 million, contingent on achieving certain milestones. This partnership is expected to significantly improve drug discovery timelines and outcomes.
Read more →SHPH▼ -13.9%on this newsshared move
Shuttle to Enter $3.24 Billion AI Pharmaceutical Market
Shuttle Pharmaceuticals Holdings, Inc. has announced a non-binding letter of intent to acquire Molecule.ai, an AI company focused on drug discovery. This acquisition aims to leverage advanced machine learning models to enhance the efficiency and accuracy of therapeutic development. The deal is valued at $10 million, contingent on achieving specific milestones.
Read more →SHPH▼ -5.1%on this news
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
Shuttle Pharmaceuticals has reported significant progress in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma, achieving 63% enrollment. The treatment has been well-tolerated, with 72% of patients completing all cycles. The company aims to complete enrollment by the end of the year, with data readouts expected in 2026.
Read more →SHPHShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
Shuttle Pharmaceuticals has successfully closed a private placement, raising $4.25 million through the issuance of shares priced at $3.60 each. The funds are intended for potential acquisitions, marketing, and general corporate purposes. The company aims to enhance cancer treatment outcomes through its innovative therapies designed to improve radiation therapy effectiveness.
Read more →SHPHShuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
Shuttle Pharmaceuticals announced a private placement agreement to raise $4.25 million through the issuance of shares priced at $3.60 each. The company plans to use the proceeds for acquisitions, marketing, and other corporate purposes. The offering is expected to close around June 23, 2025, pending customary conditions. WestPark Capital is the exclusive placement agent for this transaction.
Read more →SHPHShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
Shuttle Pharmaceuticals Holdings, Inc. announced that a reverse stock split will take effect on June 16, 2025. This move will consolidate every 25 shares into one, reducing the total shares outstanding significantly. The split is intended to help the company maintain compliance with Nasdaq's listing requirements and improve its capital structure.
Read more →SHPH▼ -34.4%on this newsshared move
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
Shuttle Pharmaceuticals Holdings, Inc. has proposed a 25-for-1 reverse stock split to comply with Nasdaq listing requirements. This move aims to reduce the number of outstanding shares significantly, from over 26 million to approximately 1 million. The company believes this action will strengthen its long-term capital structure and enhance shareholder value.
Read more →SHPH▼ -5.3%on this news· ran to +20% by day 3
Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors
Shuttle Pharmaceuticals has appointed George Scorsis as the Chairman of the Board of Directors. Scorsis, who has over 25 years of experience in various industries, aims to leverage the company's radiation sensitizers to improve cancer treatment outcomes. His leadership is expected to guide the company in enhancing the quality of life for cancer patients.
Read more →SHPHShuttle Pharma Provides Corporate Update
Shuttle Pharmaceuticals Holdings, Inc. has provided a corporate update highlighting progress in its Phase 2 clinical trial for Ropidoxuridine aimed at treating glioblastoma. The trial has seen nearly 50% patient enrollment with a high completion rate. Additionally, the company is advancing its diagnostics subsidiary and has filed a provisional patent for new cancer therapies. However, recent leadership changes could impact future operations.
Read more →SHPH▼ -13.9%on this news
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
Shuttle Pharmaceuticals is approaching 50% enrollment in its Phase 2 clinical trial for Ropidoxuridine, aimed at treating glioblastoma. The drug has demonstrated good tolerance among patients, with a low toxicity level. The trial's design includes two different dose levels to identify the optimal dosage. The company anticipates completing enrollment by the end of the year, with results expected in 2026.
Read more →SHPH▲ +20.2%on this news
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) announced its participation at the Planet MicroCap Showcase: VEGAS 2025 scheduled for April 23, 2025. The company's Chairman, Dr. Anatoly Dritschilo, will discuss updates on its ongoing Phase 2 trial of Ropidoxuridine combined with radiation therapy for glioblastoma. Additionally, advancements in the diagnostic efforts for prostate cancer through its subsidiary are expected to be presented. 1x1 meetings with management will also be available at the event.
Read more →SHPHShuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Shuttle Pharmaceuticals Holdings, Inc. will present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025. The presentation will provide updates on the Company's Phase 2 trial of Ropidoxuridine in combination with radiation therapy for glioblastoma. Additionally, information about the development of diagnostic tests for prostate cancer patients will also be shared. Dr. Anatoly Dritschilo, the Chairman and Chief Scientific Officer, will lead the presentation and participate in a Q&A session afterward.
Read more →SHPHShuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
Shuttle Pharmaceuticals has filed a provisional patent for 'PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy', which marks an important step in their development of diagnostic and therapeutic solutions for prostate cancer. The company aims to enhance outcomes for patients undergoing radiation therapy, focusing on the creation of targeted agents that leverage PSMA ligands for more effective treatment. Collaborating with accomplished medicinal chemist Dr. Alan Kozikowski, Shuttle Pharma strives to innovate within the growing market of PSMA-targeted therapies for prostate cancer.
Read more →SHPHShuttle Pharma Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer Filing provisional patent application with the USPTO entitled "PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Ther
Shuttle Pharmaceuticals has filed a provisional patent application with the USPTO for "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy." This is part of the company's efforts to advance its diagnostic subsidiary, focusing on developing targeted therapies for metastatic castration-resistant prostate cancer. The patent filing signifies a collaborative effort with Dr. Alan Kozikowski and aims to leverage PSMA ligands for effective therapy delivery and imaging, addressing an urgent need in prostate cancer treatment. The PSMA PET imaging market is projected to grow, suggesting strong commercial potential for these innovative therapeutic approaches.
Read more →SHPHShuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
Shuttle Pharmaceuticals Holdings, Inc. has successfully closed a public offering, raising approximately $5.75 million by selling 19,166,667 shares of common stock at $0.30 each. The proceeds will be utilized to fund a Phase II clinical trial for its lead product candidate, alongside marketing and working capital needs. The offering was executed by WestPark Capital, Inc., and is part of Shuttle Pharma's ongoing efforts to enhance cancer treatments through improved radiation therapy outcomes.
Read more →SHPHShuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
Shuttle Pharmaceuticals has announced the pricing of an underwritten public offering, which is expected to raise approximately $5.75 million. The funds will be allocated towards their Phase II clinical trial and general corporate purposes. The offering is said to close on March 13, 2025, pending customary conditions. Despite the optimism from the capital raised, potential investors should be aware of the risks associated with stock valuation and clinical trial outcomes.
Read more →SHPHShuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Shuttle Pharmaceuticals Holdings, Inc. appointed Christopher Cooper as interim Co-CEO to enhance its business activities and capital markets capabilities. Dr. Anatoly Dritschilo remains as Co-CEO overseeing scientific and clinical operations. The new Co-CEO structure aims to facilitate accelerated decision-making and support ongoing key clinical trials, particularly for Ropidoxuridine in glioblastoma treatment. Cooper brings over 27 years of diverse management experience and aims to improve outcomes for cancer patients.
Read more →SHPHShuttle Pharma Provides Corporate Update and Reports 2024 Results
Shuttle Pharmaceuticals Holdings, Inc. provided a corporate update alongside its 2024 annual report. Key highlights include the accelerated enrollment in a Phase 2 clinical trial for Ropidoxuridine targeting glioblastoma and advancements in its Diagnostics subsidiary through a partnership with UCSF. The company aims to enhance patient outcomes in cancer treatment via its dual approach to therapeutics and diagnostics. Management's investments reflect confidence in the company's future developments as it prepares for a significant year ahead.
Read more →SHPHShuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals has announced that it has reached 25% enrollment in its Phase 2 clinical trial for Ropidoxuridine, designed to treat glioblastoma patients. This trial involves a randomized study of two different dose levels of the drug, aiming to determine an optimal dosage. The trial targets patients with IDH wild-type, methylation negative glioblastoma, a particularly aggressive brain tumor. The company received Orphan Drug Designation from the FDA, which might provide marketing exclusivity upon approval.
Read more →SHPHShuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Shuttle Pharmaceuticals Holdings, Inc. announced that CEO Anatoly Dritschilo will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025. The discussion will cover the company's ongoing Phase 2 clinical trial of Ropidoxuridine for glioblastoma, as well as advancements in its diagnostics business. This engagement aims to enhance investor understanding of Shuttle Pharma's strategic plans and initiatives for the upcoming year.
Read more →SHPH▲ +11.3%on this news· ran to +26% by day 3
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
Shuttle Pharmaceuticals Holdings, Inc. has announced a sponsored research agreement with the University of California, San Francisco to advance the preclinical development of a novel PSMA ligand aimed at prostate cancer. This collaboration will explore the potential of the PSMA-B ligand in combination with proton therapy and its use as a PET diagnostic reagent. The agreement bolsters Shuttle's efforts in creating targeted theranostic agents, potentially impacting the treatment landscape for metastatic castration-resistant prostate cancer.
Read more →SHPHDRAFT - GOAL TO RELEASE AT TUESDAY, NOVEMBER 26 @ 9AM ET Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its F
Shuttle Pharmaceuticals Holdings, Inc. has expanded patient enrollment for its Phase 2 clinical trial of Ropidoxuridine, targeting treatment of glioblastoma. The first patient was dosed at the UVA Cancer Center as part of a broader trial that includes diverse cancer care centers across the US. The trial aims to determine the optimal dosing of Ropidoxuridine, a potential radiation sensitizer meant to improve outcomes for patients, particularly those with aggressive brain tumors. The company previously received Orphan Drug Designation from the FDA, indicating potential marketing exclusivity upon approval.
Read more →SHPHShuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
Shuttle Pharmaceuticals has announced the first patient enrollment and dosing in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment at UVA Cancer Center. This trial involves a total of 40 patients, aiming to determine the optimal dose of the radiation sensitizer. The study is significant as it targets patients with the aggressive IDH wild-type, methylation negative glioblastoma, who currently have limited treatment options. With notable cancer centers involved, the trial aims to improve treatment outcomes and patient survival rates.
Read more →SHPHShuttle Pharma Provides Third Quarter 2024 Corporate Update
Shuttle Pharmaceuticals has provided a corporate update, highlighting significant progress in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment. The company has successfully dosed its first three patients and finalized site agreements with well-known cancer centers. Additionally, Shuttle Pharma paid off its outstanding convertible note and raised funds through a public offering. The company aims to leverage radiation sensitizers to enhance cancer treatment outcomes, addressing a critical need for patients with limited effective therapies.
Read more →SHPHShuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Shuttle Pharmaceuticals Holdings, Inc. announced the pricing of a public offering expected to generate around $4.5 million, aimed at advancing clinical trials for its cancer treatment candidate Ropidoxuridine. The offering involves the sale of nearly 2.95 million shares of common stock at a price of $1.525 per share, with warrants also included. Closing of the offering is anticipated by October 31, 2024, subject to certain conditions. The proceeds will primarily support funding for Phase I and II clinical trials and working capital needs.
Read more →SHPHShuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) is set to present at the 2024 ThinkEquity Conference on October 30, 2024. CEO Dr. Anatoly Dritschilo will provide updates on the company's Phase 2 clinical trial for Ropidoxuridine aimed at treating glioblastoma. Additionally, the presentation will cover Shuttle Diagnostics' efforts to develop predictive biomarkers for prostate cancer outcomes post-radiation therapy. The conference will take place at the Mandarin Oriental Hotel, New York, accompanied by in-person meetings with investors.
Read more →SHPHShuttle Pharma Pays Off Senior Secured Convertible Note
Shuttle Pharmaceuticals Holdings, Inc. has successfully paid off its Senior Secured Convertible Note, originally due for repayment in March 2025, providing improved financial flexibility as the company advances its clinical initiatives. The company is also engaged in a Phase 2 clinical trial for glioblastoma, with multiple trial sites prepared to enroll patients. The trial will evaluate two different doses of treatment in an effort to identify the optimal dosage, aiming to improve survival rates in this challenging cancer indication.
Read more →SHPHShuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals has announced the successful dosing of the first three patients in its Phase 2 clinical trial for Ropidoxuridine, a potential treatment for glioblastoma. The trial targets aggressive brain tumors and aims to optimize dosing while assessing survival outcomes compared to historical controls. With FDA Orphan Drug Designation, the trial marks a pivotal step for patients lacking effective therapies. Results from this trial could significantly impact treatment strategies for glioblastoma, a condition with a poor prognosis.
Read more →SHPHShuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals has completed enrollment agreements with six clinical trial sites for its Phase 2 study of Ropidoxuridine in glioblastoma patients. This study, which includes prestigious cancer centers, aims to evaluate the drug's efficacy as a radiation sensitizer. With the FDA's Orphan Drug Designation, Shuttle Pharma is poised to address a crucial need for improving treatment outcomes in this aggressive form of brain cancer. The trial is set to enroll patients shortly, with results expected in the next 18 to 24 months.
Read more →SHPHShuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced that CEO Dr. Anatoly Dritschilo will present at the ThinkEquity Conference on October 30, 2024. The presentation will focus on progress towards clinical milestones for its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment. Additionally, updates regarding Shuttle Diagnostics, Inc.'s development of predictive biomarkers for prostate cancer outcomes will be provided. The company aims to enhance the effectiveness of radiation therapy for cancer patients.
Read more →SHPHShuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals Holdings has announced the expansion of site enrollment for its Phase 2 clinical trial of Ropidoxuridine, aimed at treating glioblastoma. The company has successfully onboarded two additional cancer centers, bringing the total to four out of six planned sites prepared for patient enrollment. The trial focuses on IDH wild-type, methylation negative glioblastoma patients, a cohort known for poor survival rates with standard treatments. The trial will evaluate different dosages to identify the most effective treatment approach and is expected to conclude within 18 to 24 months.
Read more →SHPHShuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
Shuttle Pharmaceuticals has announced the issuance of U.S. Patent No. 12,077,515 for selective histone deacetylase inhibitors aimed at the treatment of human diseases, including cancer. This patent, issued on September 3, 2024, adds to the company's growing intellectual property portfolio, which now exceeds 20 patents related to HDAC inhibitors across the U.S., Canada, and Europe. The company's focus is on developing novel therapeutics that improve outcomes for patients undergoing radiation therapy, marking a significant step in their clinical development efforts.
Read more →SHPHShuttle Pharma Provides Second Quarter 2024 Corporate Update
Shuttle Pharmaceuticals Holdings, Inc. has provided a corporate update revealing the launch of its Phase 2 clinical trial for Ropidoxuridine, aimed at treating glioblastoma patients. The trial has commenced with two out of six centers ready to enroll patients. Additionally, the company has achieved Orphan Drug Designation from the FDA, potentially securing marketing exclusivity. Despite recent compliance issues with Nasdaq due to a re-audit related to prior financial statements, Shuttle Pharma has regained its listing compliance.
Read more →SHPHShuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Shuttle Pharmaceuticals Holdings, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), as it traded above $1.00 per share for ten consecutive days. This compliance is crucial for maintaining its listing on the exchange and indicates a positive trend for the company’s stock performance. Shuttle Pharma specializes in developing therapies for cancer patients undergoing radiation therapy, focusing on increasing treatment effectiveness while minimizing side effects.
Read more →SHPHShuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
Shuttle Pharmaceuticals Holdings, Inc. received a notice from Nasdaq indicating it was not in compliance with Listing Rule 5250(c)(1) due to its failure to file its Q2 Quarterly Report on time. This non-compliance arose as the company is re-auditing its financial statements for 2022 following sanctions imposed on their auditor by the SEC. Shuttle Pharma plans to submit amended financial reports soon, which may allow it to regain compliance. In the meantime, the notice does not have immediate effects on the company's stock listing.
Read more →SHPHShuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals has announced the opening of patient enrollment for its Phase 2 clinical trial of Ropidoxuridine, a potential treatment for glioblastoma. The FDA has granted Orphan Drug Designation, enhancing the drug's commercialization potential. The trial will assess different dosages of Ropidoxuridine in patients with aggressive IDH wild-type, methylation negative glioblastoma, which currently has no known cure. This trial is significant as it aims to improve outcomes for patients who typically endure a poor prognosis after diagnosis.
Read more →SHPHShuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
Shuttle Pharmaceuticals announced the publication of research on SP-1-303, a selective Class I HDAC inhibitor, which demonstrates significant growth inhibition in estrogen receptor positive breast cancer cells. The study, authored by Dr. Mira Jung and Dr. Scott Grindrod, outlines SP-1-303's mechanism involving ATM activation and modulation of ER expression. The findings suggest potential for further pre-clinical evaluation and highlight the agent's ability to selectively target cancer cells while sparing normal tissues. This research supports the promise of SP-1-303 in improving outcomes for cancer patients treated with radiation therapy.
Read more →SHPHShuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
Shuttle Pharmaceuticals has appointed Timothy Lorber as Chief Financial Officer, effective September 10, 2024. Lorber, a CPA with over 40 years of experience, will initially serve part-time until his full role commences. Current CFO Michael Vander Hoek will continue as Vice President of Regulatory, allowing him to focus on regulatory matters related to the company's upcoming Phase 2 clinical trial. This leadership change is aimed at enhancing the company's capabilities in developing therapies for cancer patients undergoing radiation therapy.
Read more →SHPHShuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Shuttle Pharmaceuticals Holdings, Inc. announced that Dr. Anatoly Dritschilo, CEO, will present at the virtual Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The presentation will update investors on the Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma, focusing on improving outcomes for cancer patients treated with radiation therapy. Additionally, he will discuss the company's plans regarding Shuttle Diagnostics, including the development of predictive biomarkers for prostate cancer outcomes.
Read more →SHPHShuttle Pharma Provides First Quarter 2024 Corporate Update
Shuttle Pharmaceuticals Holdings, Inc. has provided a corporate update following its recent Quarterly Report for Q1 2024. The company has achieved FDA approval to initiate a Phase 2 clinical trial for Ropidoxuridine aimed at treating glioblastoma. Additionally, it has established a subsidiary, Shuttle Diagnostics, focused on developing diagnostic tests for prostate cancer patients. The trial is set to begin enrolling patients shortly, with results expected to provide insights into the efficacy of Ropidoxuridine as a radiation sensitizer.
Read more →SHPHShuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1×1 Meetings on Thursday, May 2, 2024
Shuttle Pharmaceuticals Holdings, Inc. will present at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024. CEO Dr. Anatoly Dritschilo will discuss the company's Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma and plans for developing predictive biomarkers for prostate cancer. The event will also include one-on-one meetings with investors on May 2, 2024.
Read more →SHPHShuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Shuttle Pharmaceuticals Holdings, Inc. announced that CEO Dr. Anatoly Dritschilo will present at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024. The presentation will cover the company's advancements in their Phase 2 Clinical Trial of Ropidoxuridine, aimed at treating glioblastoma, along with plans to develop predictive biomarkers for prostate cancer outcomes. The event will also include one-on-one investor meetings the following day, enhancing investor engagement and interest in the company’s future projects.
Read more →SHPHShuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) will have its CEO, Dr. Anatoly Dritschilo, present at the Emerging Growth Conference on April 4, 2024. The presentation will include updates on the company's subsidiary, Shuttle Diagnostics, Inc., and its efforts in developing predictive biomarkers for prostate cancer outcomes following radiation therapy. Additionally, Dr. Dritschilo will discuss a novel PSMA ligand for theranostic applications. Investors can also request virtual one-on-one meetings with the management team after the conference.
Read more →SHPHShuttle Pharma Provides Fourth Quarter 2023 Corporate Update
Shuttle Pharmaceuticals Holdings, Inc. provided a corporate update highlighting significant advancements, including FDA approval for a Phase 2 clinical trial of Ropidoxuridine aimed at glioblastoma treatment. The company is also launching Shuttle Diagnostics to develop predictive diagnostic tests for prostate cancer. A Rights Offering is planned to raise funds for these initiatives, with first patient enrollment expected in Q2 2024.
Read more →SHPHShuttle Pharma Provides Fourth Quarter 2023 Corporate Update GAITHERSBURG, Md.
Shuttle Pharmaceuticals Holdings, Inc. has provided a corporate update, announcing several key developments in its drug and diagnostic efforts. The company received FDA approval to initiate a Phase 2 clinical trial for Ropidoxuridine, targeting glioblastoma, which is expected to start in Q2 2024. Additionally, Shuttle Pharma has established a subsidiary, Shuttle Diagnostics, to focus on predictive diagnostic tests for prostate cancer, and has entered exclusive licensing agreements to enhance its biomarker program. The company also plans to raise up to $4.5 million through a Rights Offering to support its initiatives.
Read more →SHPHShuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
Shuttle Pharmaceuticals Holdings, Inc. will present at the Emerging Growth Conference on March 6, 2024, led by CEO Dr. Anatoly Dritschilo. The presentation will focus on the company’s advancements in improving cancer treatment outcomes through radiation therapy. Following the presentation, Dr. Dritschilo will engage with attendees in a Q&A session and will also be available for one-on-one investor meetings. The conference represents a strategic effort by Shuttle Pharmaceuticals to bolster investor relations and update stakeholders on its progress.
Read more →SHPHShuttle Pharma Announces Its Intent to Pursue a Rights Offering ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. has announced plans to initiate a Rights Offering to raise up to $4.5 million, aimed at providing existing stockholders the opportunity to purchase additional shares. Each subscription unit will consist of a share of common stock, a warrant, and an equity interest in its subsidiary, Shuttle Diagnostics. The company has a backstop commitment from SRO LLC, which will help ensure a minimum of $2.25 million is raised. The rights offering is pending SEC review and will be communicated to stockholders once initiated.
Read more →SHPHShuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
Shuttle Pharmaceuticals Holdings, Inc. will participate in the Lytham Partners 2024 Investor Select Conference on February 1, 2024. CEO Dr. Anatoly Dritschilo will discuss the company's recent FDA approval for a Phase II trial of Ropidoxuridine for glioblastoma. The event will include a webcast and one-on-one investor meetings.
Read more →SHPHShuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma ROCKVILLE, Md.
Shuttle Pharmaceuticals announced FDA's approval to proceed with a Phase II clinical trial of Ropidoxuridine in treating glioblastoma patients. This investigational new drug aims to enhance radiation therapy effectiveness. The company is finalizing site enrollment, expecting the first patient to receive treatment soon. Ropidoxuridine may improve survival rates and quality of life for patients, aligning with Shuttle Pharma's mission to develop innovative cancer therapies.
Read more →SHPHShuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma ROCKVILLE, Md.
Shuttle Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Ropidoxuridine, a radiation sensitizer aimed at treating glioblastoma. This submission marks a significant milestone in the development of new therapies for patients with brain tumors, which currently lack effective treatments. The planned Phase II trial will assess the safety and efficacy of Ropidoxuridine administered during radiation therapy. The company has garnered support from the National Institutes of Health and has received Orphan Drug Designation from the FDA.
Read more →SHPHShuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
Shuttle Pharmaceuticals Holdings, Inc. will present at the Emerging Growth Conference on December 7, 2023, at 10:15 am ET. CEO Dr. Anatoly Dritschilo will lead the presentation and answer questions. Attendees can access the presentation via a webcast link, and an archived version will be available afterward. One-on-one investor meetings will also be offered post-conference.
Read more →SHPHShuttle Pharmaceuticals to Present at the Emerging Growth Conference on
Shuttle Pharmaceuticals Holdings, Inc. will present at the Emerging Growth Conference on December 7, 2023, led by CEO Dr. Anatoly Dritschilo. The presentation will focus on the company's efforts to improve cancer treatment outcomes through enhanced radiation therapy. Attendees can submit questions in advance, and an archived webcast will be available for those unable to attend live. Additionally, Dr. Dritschilo will facilitate one-on-one investor meetings following the conference to discuss the company's strategies further.
Read more →SHPHShuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
Shuttle Pharmaceuticals Holdings, Inc. provided a corporate update detailing progress in its cancer treatment programs. The company received positive feedback from the FDA regarding its Ropidoxuridine clinical trial design and has licensed technology for a predictive biomarker test for prostate cancer. Additionally, Shuttle expanded its patent portfolio and published research on its HDAC6 inhibitor.
Read more →SHPHShuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. has announced significant advancements in its corporate update for Q3 2023, including favorable FDA feedback on its lead drug candidate Ropidoxuridine, intended for brain tumor treatment. The company has licensed intellectual property from Georgetown University to enhance its predictive diagnostics for prostate cancer and has expanded its patent portfolio. Additionally, it has moved into new laboratory space to bolster its research capabilities. The company expects to submit its IND application shortly to initiate a Phase 2 clinical trial.
Read more →SHPHShuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
Shuttle Pharmaceuticals has secured an exclusive license from Georgetown University to advance its predictive biomarker program for prostate cancer. This program aims to develop a diagnostic test to assess treatment success for patients considering radiation therapy. The initiative is expected to enhance decision-making for clinicians and improve patient outcomes in radiation therapy.
Read more →SHPHShuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. has announced an exclusive licensing agreement with Georgetown University to advance its predictive biomarker program for prostate cancer. This initiative aims to develop a diagnostic test that will help determine the effectiveness of radiation therapy for patients. With rising prostate cancer diagnoses, the program is designed to improve patient outcomes and clinical decision-making. The effort is part of Shuttle Pharma's broader mission to enhance cancer treatment through innovative therapies.
Read more →SHPHShuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) will participate in the Lytham Partners Fall 2023 Investor Conference on October 17, 2023. CEO Dr. Anatoly Dritschilo will present and hold one-on-one meetings with investors during the event. The conference aims to engage potential investors and showcase the company's focus on advancements in cancer treatment related to radiation therapy.
Read more →SHPHShuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
Shuttle Pharmaceuticals announced positive feedback from the FDA regarding its pre-IND meeting for Ropidoxuridine, a radiation sensitizer for glioblastoma. The FDA's guidance clarifies key aspects of the clinical protocol and Chemistry, Manufacturing, and Controls (CMC). The company aims to submit an IND application in Q4 2023 to initiate a Phase 2 clinical trial.
Read more →SHPHShuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Company remains on track to initiate the clinical trial in Q4 of 2023 ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. has announced that it received positive feedback from the FDA regarding its Ropidoxuridine Phase II clinical trial intended for glioblastoma patients. The feedback offers guidance on the company's Chemistry, Manufacturing, and Controls, as well as clinical protocol design, facilitating the submission of their Investigational New Drug application in the fourth quarter of 2023. Ropidoxuridine is positioned as a radiation sensitizer, potentially enhancing treatment outcomes for a malignancy currently without a cure. Additionally, the drug holds Orphan Drug Designation from the FDA, which could provide marketing exclusivity upon approval.
Read more →SHPHShuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men’s Health Fair
Shuttle Pharmaceuticals is participating in the Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair on September 16, 2023. The event aims to provide free early detection exams for prostate cancer, with a focus on addressing health disparities among African-American men. Dr. Tyvin Rich will discuss the company's research on prostate cancer diagnostics. Shuttle Pharma is committed to improving outcomes for patients through innovative research and community engagement.
Read more →SHPHShuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform
Shuttle Pharmaceuticals has expanded its patent portfolio with a new Canadian patent for its HDAC inhibitor platform, which includes several promising pre-clinical candidates. The company aims to enhance cancer treatment outcomes by developing therapies that sensitize cancer cells to radiation while protecting normal cells. The lead candidate, SP-2-225, is set for IND-enabling studies to advance towards a Phase I clinical trial in 2024.
Read more →SHPHShuttle Pharma’s Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics
Shuttle Pharmaceuticals announced the publication of a study demonstrating that its lead HDAC6 inhibitor, SP-2-225, can stimulate the innate immune response following radiation therapy. The research, published in Molecular Cancer Therapeutics, suggests that this selective inhibitor may improve antitumor immune responses and reduce the risk of tumor relapse. The findings support the potential of SP-2-225 as a combination therapy with radiation.
Read more →SHPHShuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
Shuttle Pharmaceuticals Holdings, Inc. has provided a corporate update, highlighting progress in its lead drug candidate, Ropidoxuridine, which is set to enter Phase II clinical trials in Q4 2023. The company has completed initial manufacturing for the drug's active ingredient and received FDA approval for a pre-IND meeting. Additionally, Shuttle Pharma has moved to new facilities to support its research and diagnostic capabilities.
Read more →SHPHShuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. has provided a corporate update highlighting significant advancements in their lead drug candidate, Ropidoxuridine, intended for brain cancer patients undergoing radiation therapy. The company has completed its initial manufacturing campaign and received FDA approval for a Type B pre-IND meeting, paving the way for a Phase II clinical trial expected to start in the fourth quarter of 2023. Additionally, the company is expanding its laboratory capabilities to support its research and diagnostic initiatives funded by NIH contracts.
Read more →SHPHShuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates
Shuttle Pharmaceuticals has entered a research agreement with Georgetown University to evaluate its lead HDAC6 inhibitor, SP-2-225, in combination with radiation therapy for breast cancer. This collaboration aims to support IND-enabling studies and initiate a Phase I clinical trial in 2024. The partnership leverages Georgetown's expertise in cellular signaling and immunology.
Read more →SHPHShuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial ROCKVILLE, Md.
Shuttle Pharmaceuticals has announced the successful completion of the manufacturing of the active pharmaceutical ingredient (API) for Ropidoxuridine, which will be used in an upcoming Phase II clinical trial focused on brain cancer patients receiving radiation therapy. The manufacturing was conducted in collaboration with TCG GreenChem and the formulation will be packaged into capsules by University of Iowa Pharmaceuticals. Additionally, the FDA approved the company’s request for a Type B pre-IND meeting, marking a significant regulatory milestone as Shuttle aims to begin the trial in the fourth quarter of 2023.
Read more →SHPHShuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update ROCKVILLE, Md.
Shuttle Pharmaceuticals has provided a corporate update for Q1 2023, highlighting several key advancements in its pipeline as it prepares for the Phase II clinical trial of its lead drug candidate, Ropidoxuridine, in brain cancer patients. The company secured manufacturing agreements and engaged a clinical research organization to assist in its studies. Additionally, Shuttle Pharma received a US patent related to cancer therapies and reported a working capital balance suggesting financial stability for operations through Q1 2025. These developments mark significant progress in their mission to improve cancer treatment outcomes.
Read more →SHPHShuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. announced that its CEO, Anatoly Dritschilo, M.D., will participate in the Lytham Partners Spring 2023 Investor Conference on May 18, 2023. During this event, he will present in a virtual panel focused on advancements in cancer treatment and engage in one-on-one meetings with potential investors. The participation demonstrates the company's commitment to improving radiation therapy outcomes for cancer patients and may enhance its visibility in the industry.
Read more →SHPHShuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial ROCKVILLE, Md.
Shuttle Pharmaceuticals has entered into an agreement with UI Pharmaceuticals to develop and manufacture clinical batches of Ropidoxuridine, intended for a Phase II clinical trial of glioblastoma treatment. This decision comes as they prepare to submit an Investigational New Drug application to the FDA by mid-2023. With Ropidoxuridine positioned as a lead clinical sensitizer, the collaboration aims to enhance outcomes for cancer patients undergoing radiation therapy.
Read more →SHPHShuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31 ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has announced that its CEO, Dr. Anatoly Dritschilo, will present at the Lytham Partners Investor Select Conference on January 31, 2023. The conference will be held virtually, and the company's presentation will be accessible via webcast. This event provides an opportunity for the company to engage with potential investors through one-on-one meetings. Shuttle Pharmaceuticals specializes in developing therapeutics to enhance the effectiveness of radiation therapy in cancer treatment.
Read more →SHPHShuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants ROCKVILLE, Md.
Shuttle Pharmaceuticals Holdings, Inc. has announced a private placement of a $4.3 million senior secured convertible note and warrant to an institutional investor. The company is set to receive initial gross proceeds of $4 million, with the potential for an additional $2.4 million if the attached warrants are exercised. This funding aims to support Shuttle's mission to enhance cancer patient outcomes during radiation therapy while minimizing side effects. The note includes flexible repayment options and bears an interest rate of 5% per annum.
Read more →SHPHShuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors ROCKVILLE, Md.
Pharmaceuticals Appoints Bette Jacobs to its Board of Directors Md., November 1, 2022 - Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with ra
Read more →SHPH▲ +91.3%on this news· ran to +160% by day 3
Shuttle Pharmaceuticals Announces Closing of Initial Public Offering
Pharmaceuticals Announces Closing of Initial Public Offering Maryland - September 6, 2022 - Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated wit
Read more →Competitive Position
How SHPH ranks across every disease it competes inCompetitive Position is a premium feature
See how SHPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial